Skip to main content
OpenTrials
Completed

NCT Number: NCT02745925

Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation

The main iron regulatory protein in the human metabolism is hepcidin. In normal weight, healthy subjects, hepcidin is regulated through the iron status of the body: low iron status results in low hepcidin concentrations, which facilitates dietary iron absorption. In obesity, which is an inflammatory state, hepcidin concentrations are increased and iron absorption is reduced despite low iron stores, leading to iron deficiency over time. Whether lowering the chronic low-grade inflammation during a limited treatment period and thereby lowering hepcidin concentration can improve iron absorption is uncertain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Human Nutrition Laboratory ETH Zurich

Zurich, 8092, Switzerland

About this study

In states of high hepcidin concentration, intestinal iron absorption (through enterocytes) and recycling of iron (through macrophages) is reduced. The extent to which non-heme iron is absorbed from the diet is influenced by the composition of the diet. Ascorbic acid is a potent enhancer of non-heme iron absorption. It's mechanism of action is luminal reduction of dietary ferric iron (Fe3+) to more soluble ferrous iron (Fe2+). A study in the inestigator's laboratory showed that the enhancing effect of ascorbic acid on non-heme iron absorption is reduced in overweight and obese individuals. Possible explanations for this fact are the different sites of action of ascorbic acid and serum hepcidin on the enterocytes in dietary iron absorption. Increased hepcidin reduces iron efflux into the circulation at the basolateral membrane of the enterocyte. Therefore the improved iron transport into enterocytes through ascorbic acid at the luminal side (via the divalent metal transporter (DMT)-1), by reducing Fe3+ to Fe2+ seems to be less successful. To improve iron absorption in obese subjects, an intervention at the basolateral membrane of the enterocyte would be needed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • normal-weight (BMI18.5-24.9kg/m2) or obesity (BMI 29-40kg/m2)
  • pre-menopausal
  • no chronic illness and no significant medical conditions that could influence iron or inflammatory status other than obesity
  • no-smoking

Exclusion criteria

  • Diagnosed chronic disease or gastrointestinal disorders
  • Metabolic disorders (e.g. diabetes)
  • Regular use of medication (except oral contraceptives)
  • Subject on a weight loss diet or planning to start a weight loss diet during the duration of the study
  • Pregnancy or lactation

Treatment and study plan

Ibuprofen

Drug

Primary outcomes

  1. Fractional iron absorption

    Time frame: Days 15 and 45

    The fractional iron absorption from four test meals will be calculated based on the shift of the iron isotopic ratios in the collected blood samples 14 days after administration of the isotopically labeled meals. Calculation of fractional iron absorption will take into account the principles of isotope dilution and the fact that iron isotopic labels are not mono-isotopic. The investigators assumed iron incorporation into erythrocytes to be constant. Blood volume, needed for the calculation of fractional iron absorption will be estimated based on available data on blood volume estimations in obese women.

Secondary outcomes

  1. Plasma ferritin

    Time frame: Days 1, 15, 30, 45

  2. Hemoglobin

    Time frame: Days 1, 15, 30, 45

  3. Transferrin receptor

    Time frame: Days 1, 15, 30, 45

  4. Hepcidin

    Time frame: Days 1, 15, 30, 45

  5. c-reactive protein

    Time frame: Days 1, 15, 30, 45

  6. interleukin-6

    Time frame: Days 1, 15, 30, 45

  7. alpha-1-acid-glycoprotein

    Time frame: Days 1, 15, 30, 45

Sponsors and collaborators

Lead sponsor

Swiss Federal Institute of Technology

Other

Collaborators

  • University of Monterrey, Mexico

Registry information

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Apr 20, 2016
Registry last updated
Oct 4, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.